

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3377935

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
GLAXOSMITHKLINE LLC		03/02/2015
RECEIVING PARTY DATA		
Name:	NOVARTIS PHARMA AG	
Street Address:	LICHTSTRASSE 35	
City:	BASEL	
State/Country:	SWITZERLAND	
Postal Code:	4056	
PROPERTY NUMBERS Total: 16		
Property Type	Number	
Application Number:	12667890	
Application Number:	14625881	
Application Number:	13500698	
Application Number:	13978765	
Application Number:	14590143	
Application Number:	13368434	
Application Number:	12526111	
Application Number:	12027454	
Application Number:	13774022	
Application Number:	14562968	
Application Number:	12695331	
Application Number:	14521593	
Application Number:	13500241	
Application Number:	14456180	
Application Number:	14543126	
Application Number:	14565691	
CORRESPONDENCE DATA		
Fax Number:	(703)739-2815	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		

PATENT

Email: iprecordals@cpaglobal.com, gpillai1@cpaglobal.com
Correspondent Name: CPA GLOBAL LIMITED
Address Line 1: LIBERATION HOUSE
Address Line 2: CASTLE STREET
Address Line 4: ST HELIER, JERSEY JE1 1BL

NAME OF SUBMITTER: HELEN BIRRELL


SIGNATURE: /H/BIRRELL/IPR/GP/NOVARTGSK/AI6H1/16P/US

DATE SIGNED: 06/02/2015

Total Attachments: 56

source=AG D#page1.tif
source=AG D#page2.tif
source=AG D#page3.tif
source=AG D#page4.tif
source=AG D#page5.tif
source=AG D#page6.tif
source=AG D#page7.tif
source=AG D#page8.tif
source=AG D#page9.tif
source=AG D#page10.tif
source=AG D#page11.tif
source=AG D#page12.tif
source=AG D#page13.tif
source=AG D#page14.tif
source=AG D#page15.tif
source=AG D#page16.tif
source=AG D#page17.tif
source=AG D#page18.tif
source=AG D#page19.tif
source=AG D#page20.tif
source=AG D#page21.tif
source=AG D#page22.tif
source=AG D#page23.tif
source=AG D#page24.tif
source=AG D#page25.tif
source=AG D#page26.tif
source=AG D#page27.tif
source=AG D#page28.tif
source=AG D#page29.tif
source=AG D#page30.tif
source=AG D#page31.tif
source=AG D#page32.tif
source=AG D#page33.tif
source=AG D#page34.tif
source=AG D#page35.tif
source=AG D#page36.tif
source=AG D#page37.tif

source=AG D#page38.tif
source=AG D#page39.tif
source=AG D#page40.tif
source=AG D#page41.tif
source=AG D#page42.tif
source=AG D#page43.tif
source=AG D#page44.tif
source=AG D#page45.tif
source=AG D#page46.tif
source=AG D#page47.tif
source=AG D#page48.tif
source=AG D#page49.tif
source=AG D#page50.tif
source=AG D#page51.tif
source=AG D#page52.tif
source=AG D#page53.tif
source=AG D#page54.tif
source=AG D#page55.tif
source=AG D#page56.tif



Ox_Glo5A_IP Assignment Agreement

EXECUTION VERSION

Date: 2 March 2015

GLAXO GROUP LIMITED

GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED

GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED

GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED

SMITHKLINE BEECHAM LIMITED

SMITHKLINE BEECHAM (CORK) LIMITED

GLAXOSMITHKLINE INC.

GLAXOSMITHKLINE FOOD

GLAXOSMITHKLINE LLC

GLAXOSMITHKLINE CONSUMER HEALTHCARE IRELAND IP LIMITED

GLAXOSMITHKLINE GMBH & CO. KG

GROUPE GLAXOSMITHKLINE S.A.S.

GLAXOSMITHKLINE S.P.A.

GLAXOSMITHKLINE K.K.

GLAXOSMITHKLINE AUSTRALIA PTY LTD

GLAXOSMITHKLINE BRASIL LIMITADA

LABORATOIRE GLAXOSMITHKLINE

GLAXOSMITHKLINE HOLDING AS

GLAXOSMITHKLINE INTELLECTUAL PROPERTY HOLDINGS LIMITED

GLAXOSMITHKLINE PLC

and

NOVARTIS PHARMA AG

INTELLECTUAL PROPERTY ASSIGNMENT

Slaughter and May,
One Bunhill Row,
London EC1Y 8YY
Ref: SXXM/LVH/SOM

S25750297

LCI04911049/8 125114-0031

EXECUTION VERSION

THIS ASSIGNMENT is made

~~2 March 2015~~ 2 March 2015
FSD
SM

BETWEEN:

- (1) GLAXO GROUP LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 00305979 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (2) GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 08283282 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (3) GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 07739397 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (4) GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 08283185 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (5) SMITHKLINE BEECHAM LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 02337959 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (6) SMITHKLINE BEECHAM (CORK) LIMITED, a company duly incorporated under the laws of Ireland with company registration number 217025 and whose registered office is at Carrabinny, Carrigaline, County Cork, Ireland;
- (7) GLAXOSMITHKLINE LLC, a company duly incorporated under the laws of the United States with company registration number 4746253 and whose registered office is at Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware, 19808, United States;
- (8) GLAXOSMITHKLINE INC., a company duly incorporated under the laws of Canada with company registration number 802605-0 and whose registered office is at 7333 Mississauga Road North, Mississauga, L6N 6L4, Canada;
- (9) LABORATOIRE GLAXOSMITHKLINE, a company duly incorporated under the laws of France with company registration number B 642.041.382 and whose registered office is at 100 Route de Versailles, Marly le Roi, 78160, France;
- (10) GLAXOSMITHKLINE EOOD, a company duly incorporated under the laws of Bulgaria with company registration number 10240/2003 and whose registered office is at 115 G Tsarigradsko Shose Blvd., floor 9, Mladost Region, Sofia, 1784, Bulgaria;
- (11) GLAXOSMITHKLINE CONSUMER HEALTHCARE IRELAND IP LIMITED, a company duly incorporated under the laws of Ireland with company registration number 553895 and whose registered office is at Carrabinny, Carrigaline, County Cork, Ireland;
- (12) GLAXOSMITHKLINE GMBH & CO. KG, a limited liability partnership duly incorporated under the laws of Germany with company registration number HRA 78754 and whose registered office is at Prinzregentenplatz 3, Munchen, 81675, Germany;

LON480110098 133114-0021

EXECUTION VERSION

3

- (13) GROUPE GLAXOSMITHKLINE S.A.S., a company duly incorporated under the laws of France with company registration number Versailles B 552 052 146 and whose registered office is at 100 Route de Versailles, Marly le Roi, 78180, France;
- (14) GLAXOSMITHKLINE S.P.A. a company duly incorporated under the laws of Italy with company registration number 00212840235 and whose registered office is at Via Alessandro Fleming 2, Verona, 37135, Italy;
- (15) GLAXOSMITHKLINE K.K., a company duly incorporated under the laws of Japan with company registration number 0110-01-026329 and whose registered office is at 4-6-15 Sendagaya, Shibuya-ku, Tokyo, 151-8566, Japan;
- (16) GLAXOSMITHKLINE AUSTRALIA PTY LTD, a company duly incorporated under the laws of Australia with company registration number ACN 100 162 481 and whose registered office is at 1061 Mountain Highway, Boronia, 3155, Australia;
- (17) GLAXOSMITHKLINE BRASIL LIMITADA, a company duly incorporated under the laws of Brazil with company registration number CNPJ/MF 33.247.743/0001-10 and whose registered office is at Estrada dos Bandeirantes, 8464, Rio de Janeiro, 22783-110, Brazil;
- (18) GLAXOSMITHKLINE HOLDING AS, a company duly incorporated under the laws of Norway with company registration number 919157445 and whose registered office is at Klaus Torgårds vei 3, Oslo, NO-0372, Norway;
- (19) GLAXOSMITHKLINE INTELLECTUAL PROPERTY HOLDINGS LIMITED, a company duly incorporated under the laws of England and Wales with company registration number 06263269 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England;
- (each an "Assignor" and in the plural the "Assignors");
- (20) GLAXOSMITHKLINE PLC, a public limited company incorporated in England and Wales with company registration number 03886792 and whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, England ("GSK");
- (21) NOVARTIS PHARMA AG, a company duly incorporated in Switzerland and whose registered office is at Lichtstrasse 35, 4056 Basel, Switzerland (the "Assignee").

WHEREAS:-

- (A) Novartis AG ("Novartis") and GlaxoSmithKline plc ("GSK") are parties to a sale and purchase agreement dated 22 April 2014, as amended and restated on 29 May 2014 and as further amended and restated on 21 November 2014 and again on or about the date of this Assignment, (the "Sale and Purchase Agreement"), pursuant to which GSK has agreed, inter alia, to transfer its oncology research, development and commercialisation business to Novartis and Novartis has agreed to purchase the same.
- (B) Pursuant to the Sale and Purchase Agreement and subject to the terms of this Assignment, each Assignor has agreed to assign to the Assignee all right, title and interest in and to its rights:
- (i) in the Transferred Product Intellectual Property Rights, including (without limitation) any such rights held by it in:
- (1) the Patents, Patent Term Extensions and supplementary protection certificates, details of which are set out in Schedule 1 Part A hereto (the "Assigned Patents");

LON340119474 155114-0011

EXECUTION VERSION

4

- (2) the Trademarks, details of which are set out in Schedule 2 hereto (the "Assigned Trade Marks");
 - (3) the domain names, details of which are set out in Schedule 3 hereto (the "Assigned Domain Names"); and
 - (4) the Copyrights, details of which are set out in Schedule 4 hereto (the "Assigned Copyrights"); and
 - (5) the Transferred Product Intellectual Property Rights which are not Registered Transferred Product Intellectual Property Rights and excluding anything included in (B)(i)(1) to (4) above (the "Assigned Unregistered IP");
- (B) under the agreements set out at Schedule 5 hereto, each as amended from time to time, (the "Licence Agreements"), in so far as such rights relate to Transferred Product Intellectual Property Rights (the "Assigned Licensed Rights"); and
- (iii) in the Abandoned Patents relating to any Assigned Patents (the "Assigned Abandoned Patents"), to the extent it has any rights in the same and subject to the terms of the Sale and Purchase Agreement in respect of such assignment.

NOW IT IS HEREBY AGREED as follows:-

1. DEFINITIONS AND INTERPRETATION

- 1.1 "Abandoned Patents" means any Patent Exclusively Related to the Business abandoned by a member of the Seller's Group before Closing from which an Assigned Patent can claim priority, or from the priority chain of which a right to priority can be claimed in respect of an Assigned Patent.
- 1.2 "Co-owned Assigned IP" means any Assigned Patent, Assigned Trade Mark, Assigned Copyright, Assigned Domain Name and Assigned Unregistered IP that is owned in part by a third party.
- 1.3 "Exclusively Related to the Business" means exclusively related to, or exclusively used or held for use exclusively in connection with, the Business.
- 1.4 "Patents" means, patents, design patents, patent applications, and any reissues, re-examinations, divisionals, continuations, continuations-in-part, provisionals, and extensions thereof or any counterparts to any of the foregoing (including rights resulting from any post-grant proceedings relating to any of the foregoing)
- 1.5 "Third Party Consent" means any consent, licence, approval, permit, authorisation or waiver required from a third party for the assignment or transfer to the Assignee of any of the Co-owned Assigned IP.
- 1.6 Unless otherwise defined in this Assignment capitalised terms have the meaning given to those terms in the Sale and Purchase Agreement.

2. CONSIDERATION

- 2.1 The good and valuable consideration given by or on behalf of the Assignee is the amount provided under the Sale and Purchase Agreement (taking into account, for the avoidance of doubt, any reduction to the Business

LON34011049/A 153114-0011

Consideration pursuant to Clause 6.3.3 of the Sale and Purchase Agreement), the receipt and sufficiency of which is hereby acknowledged by GSK on behalf of the Assignors.

2.2 GSK has received such amounts as are paid to it in accordance with clause 2.1 on behalf of the Assignors.

3. ASSIGNMENT

3.1 With effect from Closing, each Assignor hereby assigns to the Assignee all its right, title and interest in and to its rights:

(A) In the Transferred Product Intellectual Property Rights, including (without limitation) any such rights held by it in:

- (i) the Assigned Patents, together with all rights, privileges and advantages thereto, including, without limitation, the right to take, defend, or appeal proceedings and recover (and retain) damages, and obtain all other remedies in respect of past infringements thereof, and the right to claim priority from any patent application therein, including the right to claim priority from the priority chain of any such patent application, to hold unto the Assignee absolutely for the full term of the Assigned Patents;
- (ii) the Assigned Trade Marks, together with all associated goodwill including any associated Business Goodwill (if any), including all rights, privileges and advantages thereto, including, without limitation, the right to take, defend, or appeal proceedings and recover (and retain) damages, and obtain all other remedies in respect of past infringements thereof, and the right to claim priority from any trademark application therein, including the right to claim priority from the priority chain of any such trademark application, to hold unto the Assignee absolutely for the full term of the Assigned Trade Marks;
- (iii) the Assigned Domain Names, together with all rights, privileges and advantages thereto, including, without limitation, the right to take, defend, or appeal proceedings and recover (and retain) damages and obtain all other remedies in respect of past misappropriations or infringements thereof, to hold unto the Assignee absolutely for the full term of the Assigned Domain Names;
- (iv) the Assigned Copyrights, together with all rights, privileges and advantages thereto, including, without limitation, the right to take, defend, or appeal proceedings and recover (and retain) damages, and obtain all other remedies in respect of past infringements thereof, to hold unto the Assignee absolutely for the full term of the Assigned Copyrights; and
- (v) the Assigned Unregistered IP, together with all associated goodwill including any associated Business Goodwill (if any), together with all rights, privileges and advantages thereto including, without limitation, the right to take, defend, or appeal proceedings and recover (and retain) damages and obtain all other remedies in respect of past infringements thereof, to hold unto the Assignee absolutely for the full term of the Assigned Unregistered IP;

but excluding, for the avoidance of doubt, any Transferred Intellectual Property Contracts;

(B) In the Assigned Licensed Rights; and

- (C) in the Assigned Abandoned Patents, together with the right to claim priority from any Assigned Abandoned Patent, including the right to claim priority from the priority chain of any such Assigned Abandoned Patent, subject to the terms of the Sale and Purchase Agreement in respect of such assignment and to the extent (i) it has any rights in the same; and (ii) permissible under Applicable Law in the country of any such Abandoned Patent,

except in so far as any rights under 3.1(A), (B) and (C) relate to Ukraine ("Delayed Territory Rights"), including (without limitation) any rights held by each of them in the Patents, Patent Term Extensions and Trade Marks which are set out at Schedule 6 hereto.

- 3.2 On the Delayed Closing Date in respect of the Ukraine Business, each relevant Assignor shall deliver to the Assignee and the Assignee shall deliver to each relevant Assignor a duly executed assignment agreement in substantially the same form as this Assignment in respect of the assignment of all of such Assignor's right, title and interest in the Delayed Territory Rights, including (without limitation) (i) the Patents, Patent Term Extensions and supplementary protection certificates, details of which are set out in Schedule 6 Part A hereto; and (ii) the Trademarks, details of which are set out in Schedule 6 Part B hereto.
- 3.3 This Assignment is executed for the purpose of evidencing and confirming the transfer of the (i) Transferred Product Intellectual Property Rights; and (ii) Assigned Abandoned Patents to the Assignee as provided in the Sale and Purchase Agreement. Nothing contained in this Assignment is intended to modify any of the provisions of the Sale and Purchase Agreement as they relate to the (i) Transferred Product Intellectual Property Rights, including any of the representations, warranties, covenants or indemnities set forth in the Sale and Purchase Agreement; and (ii) Assigned Abandoned Patents. In the event of any conflict between this Assignment and the Sale and Purchase Agreement, the Sale and Purchase Agreement will prevail.
- 3.4 In relation to any Co-owned Assigned IP which is not assignable without Third Party Consent, this Agreement shall not be construed as an assignment or an attempted assignment (nor, for the avoidance of doubt, a sub-licensing or an attempted sub-licensing) of any such Co-owned Assigned IP where the relevant Third Party Consent has not been obtained on or prior to the date of this Agreement. Without prejudice to this Clause 3.4, paragraphs 4 (Obligation to obtain Third Party Consents), 5 (Obligations until Third Party Consents are obtained/where Third Party Consents are refused and with respect to Non-Transferring Tenders) and 6 (Failure to Obtain Third Party Consents) (inclusive) of Schedule 7 of the Sale and Purchase Agreement shall apply to any such Co-owned Assigned IP that is not assigned pursuant to this Agreement. For the avoidance of doubt, references in paragraphs 4 (Obligation to obtain Third Party Consents), 5 (Obligations until Third Party Consents are obtained/where Third Party Consents are refused and with respect to Non-Transferring Tenders) and 6 (Failure to Obtain Third Party Consents) (inclusive) of Schedule 7 of the Sale and Purchase Agreement to 'Co-Owned Transferred Intellectual Property Rights' shall include Co-Owned Assigned IP.
4. RECORDALS AND FURTHER ASSURANCE
- 4.1 Clause 8.13 of the Sale and Purchase Agreement applies to this Assignment (save in respect of the assignment of any rights under Clause 3.1(C) of this Assignment) and is hereby incorporated herein by reference.
- 4.2 Clause 8.18 of the Sale and Purchase Agreement applies to the assignment of any rights under Clause 3.1(C) of this Assignment and is hereby incorporated herein by reference.

5. OTHER PROVISIONS

5.1 For the avoidance of doubt, clauses 16.1 to 16.5 (inclusive) and 16.11 to 16.13 (inclusive) of the Sale and Purchase Agreement apply to this Assignment *mutatis mutandis* and are hereby incorporated herein by reference.

6. GOVERNING LAW

6.1 This Assignment and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with English law.

6.2 Each of the parties irrevocably agrees that the courts of England and Wales are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Assignment and that accordingly any proceedings arising out of or in connection with this Assignment shall be brought in such courts. Each of the parties irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have been brought in an inconvenient forum.

EXECUTION VERSION

IN WITNESS WHEREOF this Assignment has been executed by or on behalf of the parties on the date first above written.

Signed by

for and on behalf of GLAXO GROUP LIMITED

(Authorised signatory(ies))

Signature page 1 of 21

EXECUTION VERSION

9

Signed by }
for and on behalf of GLAXOSMITHKLINE }
INTELLECTUAL PROPERTY (NO. 2) LIMITED } (Authorised signatory(ies))

Signature page 2 of 21

EXECUTION VERSION

10

Signed by
for and on behalf of GLAXOSMITHKLINE
INTELLECTUAL PROPERTY MANAGEMENT
LIMITED
(Authorised signatory(ies))

Signature page 3 of 21

EXECUTION VERSION

11

Signed by }
for and on behalf of GLAXOSMITHKLINE }
INTELLECTUAL PROPERTY LIMITED } (Authorised signatory(ies))

Signature page 4 of 21

EXECUTION VERSION

12

Signed by
for and on behalf of SMITHKLINE BEECHAM
LIMITED

.....
(Authorised signatory(ies))

Signature page 5 of 21

EXECUTION VERSION

13

Signed by

)

)

.....

for and on behalf of SMITHKLINE BEECHAM

)

(Authorised signatory(ies))

(CORK) LIMITED

)

Signature page 6 of 21

EXECUTION VERSION

14

Signed by
for and on behalf of GLAXOSMITHKLINE LLC
(Authorised signatory(ies))

Signature page 7 of 21

EXECUTION VERSION

15

Signed by

for and on behalf of GLAXOSMITHKLINE INC.

.....
(Authorized signatory(ies))

Signature page 8 of 21

EXECUTION VERSION

16

Signed by	}	
	}	
for and on behalf of LABORATOIRE	}	(Authorised signatory(ies))
GLAXOSMITHKLINE	}	

Signature page 9 of 21.

EXECUTION VERSION

17

Signed by }
for and on behalf of GLAXOSMITHKLINE EOOD }
} (Authorised signatory(ies))
}

Signature page 16 of 21

EXECUTION VERSION

18

Signed by }
..... }
for and on behalf of GLAXOSMITHKLINE } (Authorised signatory(ies))
CONSUMER HEALTHCARE IRELAND IP }
LIMITED }

Signature page 11 of 21

EXECUTION VERSION

19

Signed by

for and on behalf of GLAXOSMITHKLINE GMBH
& CO. KG

.....
(Authorised signatory(ies))

Signature page 12 of 21

EXECUTION VERSION

20

Signed by

for and on behalf of GROUPE
GLAXOSMITHKLINE S.A.S.

}
}
}
}

.....
(Authorised signatory(ies))

Signature page 13 of 21

EXECUTION VERSION

21

Signed by

for and on behalf of GLAXOSMITHKLINE S.P.A.

(Authorised signatory(ies))

Signature page 14 of 21

EXECUTION VERSION

23

Signed by

for and on behalf of GLAXOSMITHKLINE

AUSTRALIA PTY LTD

(Authorised signatory(ies))

Signature page 16 of 21

EXECUTION VERSION

24

Signed by

for and on behalf of GLAXOSMITHKLINE
BRASIL LIMITADA

.....
(Authorised signatory(ies))

Signature page 17 of 21

EXECUTION VERSION

25

Signed by	}	
	}	
for and on behalf of GLAXOSMITHKLINE	}	(Authorised signatory(ies))
HOLDING AS	}	

Signature page 18 of 21

EXECUTION VERSION

26

Signed by

for and on behalf of GLAXOSMITHKLINE
INTELLECTUAL PROPERTY HOLDINGS
LIMITED

.....
(Authorised signatory(ies))

Signature page 19 of 21

EXECUTION VERSION

27

Signed by

for and on behalf of GLAXOSMITHKLINE PLC

.....
(Authorised signatory(ies))


Signature page 20 of 21

EXECUTION VERSION


28

Roy Papatheodorou
As Attorney

Signed by


.....
(Authorised signatory (ent))

Signed by SANTIWONG JONGSARTIWANG
AS ATTORNEY


.....
(Authorised signatory (ent))

for and on behalf of NOVARTIS PHARMA AG

Signature page 21 of 21

EXECUTION VERSION

36

Case No.	Relation Type Code	Filing No.	Case Type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
AKT	PUG3961	ORG	REG	Granted	China P.R.	201080056873.2	08-Oct-2010	28-Oct-2014	ZL201080056873.2	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Filed	Eurasian Patent Convention	201270526	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	European Patent Convention	10822733.1	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	France	10822733.1	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	Germany	EP2485593	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Filed	Israel	218899	08-Oct-2010		602010021721.3	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	Italy	10822733.1	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Filed	Japan	2012-533334	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	Mexico	MX/A/2012/004139	08-Oct-2010	14-Oct-2014	324516	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Filed	Republic of Korea	10-2012-7011758	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	Singapore	201202337.0	08-Oct-2010	30-Oct-2014	175763	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	South Africa	201202494	08-Oct-2010	27-Dec-2012	201202494	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	Spain	10822733.1	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	United Kingdom	10822733.1	08-Oct-2010	07-Jan-2015	EP2485593	GlaxoSmithKline LLC
AKT	PUG3961	C	REG	Filed	United States	14436180	11-Aug-2014			GlaxoSmithKline LLC
AKT	PUG3961	ORG	REG	Granted	United States	13/503241	08-Oct-2010	16-Sep-2014	8835450	GlaxoSmithKline LLC
AKT	PUG3962	ORG	REG	Granted	Australia	201030384	08-Oct-2010	02-Jan-2014	201030384	GlaxoSmithKline LLC
AKT	PUG3962	ORG	REG	Filed	Brazil	BR112012008274.4	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUG3962	ORG	REG	Filed	Canada	2777087	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUG3962	ORG	REG	Granted	China P.R.	201080056874.7	08-Oct-2010	19-Feb-2014	ZL201080056874.7	GlaxoSmithKline LLC
AKT	PUG3962	ORG	REG	Filed	Eurasian Patent	201270527	08-Oct-2010			GlaxoSmithKline LLC

LON340110459/4 153114-0031

EXECUTION VERSION

37

Patent No.	Case No.	Ref. No.	Filing No.	Case Type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
AKT	PUB3962	ORG		REG	Granted	European Patent Convention	10622734.9	06-Oct-2010	07-Jan-2015	EP2485594	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	France	10622734.9	08-Oct-2010	07-Jan-2015	EP2485594	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	Germany	EP2485594	08-Oct-2010	07-Jan-2015	602010021722	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Filed	Israel	219000	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	Italy	10822734.9	08-Oct-2010	07-Jan-2015	EP2485594	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Filed	Japan	2012-533335	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	Mexico	MX/A/2012/004140	08-Oct-2010	14-Oct-2014	324517	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Filed	Republic of Korea	10-2012-7011759	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Filed	Singapore	201202398-8	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	South Africa	2012/02495	08-Oct-2010	30-Jan-2013	2012/02495	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	Spain	10622734.9	08-Oct-2010	07-Jan-2015	EP2485594	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	United Kingdom	10822734.9	08-Oct-2010	07-Jan-2015	EP2485594	GlaxoSmithKline LLC
AKT	PUB3962	ORG		REG	Granted	United States	13/630698	08-Oct-2010	05-Aug-2014	8796298	GlaxoSmithKline LLC
AKT	PUB4243	ORG		REG	Filed	European Patent Convention	11784238.5	16-May-2011			GlaxoSmithKline LLC
AKT	PUB4243	C	C1	REG	Filed	United States	14/043123	17-Nov-2014			GlaxoSmithKline LLC
AKT	PUB4255	ORG		REG	Filed	European Patent Convention	11787314.1	25-May-2011			GlaxoSmithKline LLC
AKT	PUB4255	ORG		REG	Filed	Japan	2013-512197	25-May-2011			GlaxoSmithKline LLC
AKT	PUB4255	C	C1	REG	Filed	United States	14/066661	10-Dec-2014			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Australia	2012205501	11-Jan-2012			GlaxoSmithKline LLC

LON340119494 15114-0011

PATENT

REEL: 035806 FRAME: 0504

EXECUTION VERSION

38

Patent No.	Case No.	Reason Type	Filing No.	Case Type	Status	Country	Application Number	Appreciation Date	Grant Date	Patent Number	Legal Owner
AKT	PUB4479	ORG		REG	Filed	Brazil	BR112013017722-5	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Canada	2824201	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	China P.R.	201280048300.0	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Eurasian Patent Convention	201391027	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	European Patent Convention	12733910.6	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Israel	227097	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Japan	2013-548503	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Mexico	MX/A/2013/006074	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Republic of Korea	10-2013-7021098	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	Singapore	201304385-6	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	South Africa	2013/04139	11-Jan-2012	26-Feb-2014	201304139	GlaxoSmithKline LLC
AKT	PUB4479	ORG		REG	Filed	United States	13/678765	11-Jan-2012			GlaxoSmithKline LLC
AKT	PUB4479-1	C	C1	REG	Filed	United States	14/590143	08-Jan-2015			GlaxoSmithKline LLC
AKT	PUB4479-1	P		REG	Filed	United States	13/688434	08-Feb-2012			GlaxoSmithKline LLC
AKT	PUB6165	ORG		REG	Filed	Algeria	140645	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB6165	ORG		REG	Filed	Argentina	20130101336	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB6165	ORG		REG	Filed	Australia	2013254949	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB6165	ORG		REG	Filed	Bangladesh	77/2013	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited

CON3401104/64 155114-0031

PATENT

REEL: 035806 FRAME: 0505

EXECUTION VERSION

33

Product	Case No.	Relation Type Code	Filing No.	Case Type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
AKT	PU62316	ORG		REG	Granted	Turkey	08729249.6	07-Feb-2008	25-Jun-2014	EP2117523	GlaxoSmithKline LLC
AKT	PU62318	ORG		REG	Granted	Turkmenistan	2009/0749	07-Feb-2008	30-May-2013	016036	GlaxoSmithKline LLC
AKT	PU62316	ORG		REG	Granted	United Kingdom	08729249.6	07-Feb-2008	25-Jun-2014	EP2117523	GlaxoSmithKline LLC
AKT	PU62316	C	C1	REG	Granted	United States	13/774022	22-Feb-2013	03-Feb-2015	8946276	GlaxoSmithKline LLC
AKT	PU62316	C	C2	REG	Filed	United States	14/582968	08-Dec-2014			GlaxoSmithKline LLC
AKT	PU62316	ORG	T	REG	Granted	United States	12/027454	07-Feb-2008	25-Sep-2012	8275782	GlaxoSmithKline LLC
AKT	PU62316	ORG		REG	Granted	United States	12/020111	07-Feb-2008	02-Apr-2013	8410158	GlaxoSmithKline LLC
AKT	PU62316	ORG		REG	Filed	Uruguay	30.892	01-Feb-2008			GlaxoSmithKline LLC
AKT	PU62316	ORG		REG	Filed	Venezuela	2202/008	06-Feb-2008			GlaxoSmithKline LLC
AKT	PU62316	ORG		REG	Granted	Vietnam	1-2009-01892	07-Feb-2008	12-May-2014	12710	GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Filed	Algeria	110571	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Filed	Argentina	P160100226	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Granted	Armenia	201101144	28-Jan-2010	29-Nov-2013	016907	GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Granted	Australia	2010208265	28-Jan-2010	25-Mar-2013	2010208265	GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Granted	Azerbaijan	201101144	28-Jan-2010	29-Nov-2013	016907	GlaxoSmithKline LLC
AKT	PU62460	ORG		9	Filed	Bangladesh	26/2010	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Granted	Belarus	201101144	28-Jan-2010	29-Nov-2013	016907	GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Filed	Brazil	P110068896-1	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Filed	Canada	2750565	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Filed	Chile	2011-1830	28-Jan-2010			GlaxoSmithKline LLC
AKT	PU62460	ORG		REG	Granted	China P.R.	201080015363.2	28-Jan-2010	08-Jul-2014	ZL201080015363.2	GlaxoSmithKline LLC

LON34011049/4 (35114-003)

PATENT

REEL: 035806 FRAME: 0506

EXECUTION VERSION

35

Product	Case No.	Reason Type Code	Filing No.	Case Type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
AKT	PUB3460	ORG		REG	Filed	Nigeria	NGC/2011/534	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Pakistan	57/2010	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Peru	001368-2011/DIN	28-Jan-2010	03-Jul-2014	7185	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Philippines	1-2011-501462	28-Jan-2010	21-May-2014	1-2011-501462	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Republic of Korea	10-2011-701784S	28-Jan-2010	10-Jul-2014	10-1420484	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Russian Federation	201101114	28-Jan-2010	29-Nov-2013	018907	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Singapore	201105014-3	28-Jan-2010	15-May-2012	172926	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	South Africa	201305033	28-Jan-2010	28-Mar-2012	201305033	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Taiwan	99102341	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Tajikistan	201101114	28-Jan-2010	29-Nov-2013	018907	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Thailand	1101001331	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Trinidad & Tobago	TT/A/2011/00135	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	Turkmenistan	201101114	28-Jan-2010	29-Nov-2013	018907	GlaxoSmithKline LLC
AKT	PUB3460	C	TC2	REG	Filed	United States	44521823	23-Oct-2014			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Granted	United States	12066331	28-Jan-2010	17-Dec-2013	8609711	GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Uruguay	32407	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Venezuela	115/2010	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3460	ORG		REG	Filed	Vietnam	1-2011-02280	28-Jan-2010			GlaxoSmithKline LLC
AKT	PUB3961	ORG		REG	Granted	Australia	2010303363	08-Oct-2010	16-Dec-2013	2010303363	GlaxoSmithKline LLC
AKT	PUB3961	ORG		REG	Filed	Brazil	BR112012008271-0	08-Oct-2010			GlaxoSmithKline LLC
AKT	PUB3961	ORG		REG	Filed	Canada	277065	08-Oct-2010			GlaxoSmithKline LLC

LON340119492 155114-0931

PATENT

REEL: 035806 FRAME: 0507

Patent No.	Applicant	Inventor	IPC Class.	Pub. No.	Pub. Date	Grant No.	Grant Date	Term	Legal Status	Log. Owner
PROMACTA (EP11141141)	D	D2	REG	Granted	Sweden	07112106.5	17-Aug-2007	14-Oct-2008	EP1889838	Glaxo Group Limited
PROMACTA (EP11141141)	ORG	PTE	J	Granted	Sweden	1080021-5	05-May-2010	02-Nov-2010	1080021-5	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		REG	Granted	Sweden	01541599.1	24-May-2001	03-Oct-2007	1294378	Glaxo Group Limited
PROMACTA (EP11141141)	D	D1	REG	Granted	Switzerland	07112106.7	17-Aug-2007	22-Jul-2009	EP1864981	Glaxo Group Limited
PROMACTA (EP11141141)	D	D2	REG	Granted	Switzerland	07112106.5	17-Aug-2007	14-Oct-2009	EP1898938	Glaxo Group Limited
PROMACTA (EP11141141)	ORG	PTE	J	Granted	Switzerland	CO1294378-01	19-Jul-2010	31-May-2013	x	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		REG	Granted	Switzerland	01541599.1	24-May-2001	03-Oct-2007	1294378	Glaxo Group Limited
PROMACTA (EP11141141)	ORG	PTE	J	Filed	Taiwan	80412317	19-Dec-2014			Glaxo Group Limited
PROMACTA (EP11141141)	ORG		REG	Granted	Taiwan	50112317	23-May-2001	11-Jan-2009	1805207	Glaxo Group Limited
PROMACTA (EP11141141)	D	D1	REG	Granted	Turkey	EP1664981	17-Aug-2007	22-Jul-2009	TR20090752874	Glaxo Group Limited
PROMACTA (EP11141141)	D	D2	REG	Granted	Turkey	EP1889838	17-Aug-2007	14-Oct-2009	TR20100029974	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		REG	Granted	Turkey	1294378	24-May-2001	03-Oct-2007	TR20070885714	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		C	Granted	Turks & Caicos	10089	24-Jul-2008	10-Nov-2009	10089	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		C	Granted	Tuvalu	EP1294378	29-Jul-2008	08-Sep-2008	TVP1294378	Glaxo Group Limited
PROMACTA (EP11141141)	D	D1	REG	Granted	United Kingdom	07112105.7	17-Aug-2007	22-Jul-2009	EP1864981	Glaxo Group Limited
PROMACTA (EP11141141)	D	D2	REG	Granted	United Kingdom	07112106.5	17-Aug-2007	14-Oct-2009	EP1889838	Glaxo Group Limited
PROMACTA (EP11141141)	ORG	PTE	J	Granted	United Kingdom	SPC/GB10/026	19-Apr-2010	20-Feb-2012	SPC/GB10/026	Glaxo Group Limited
PROMACTA (EP11141141)	ORG		REG	Granted	United Kingdom	01541599.1	24-May-2001	03-Oct-2007	1294378	Glaxo Group Limited
PROMACTA (EP11141141)	C	C10	REG	Filed	United States	133533739	24-Aug-2012			Glaxo Group Limited

	Patent No.	Inventor	Type	Status	Country	Application Number	Date of Filing	Grant Date	Valid Until	Legal Owner
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Moldova	201290149	15-Oct-2010	30-Dec-2014	020583	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Morocco	34833	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	New Zealand	596913	15-Oct-2010	04-Mar-2014	596913	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Nigeria	NG/C/2012/110	15-Oct-2010	01-Mar-2013	NG/C/2012/110	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Peru	000602-2012/DN	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Philippines	1-2012-500742	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Republic of Korea	10-2012-7012649	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Russian Federation	204290149	15-Oct-2010	30-Dec-2014	020586	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Singapore	201202762-B	15-Oct-2010	27-Oct-2014	180384	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	South Africa	201202612	15-Oct-2010	25-Sep-2013	201202612	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Tajikistan	204290149	15-Oct-2010	30-Dec-2014	020589	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Thailand	1201001391	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Trinidad & Tobago	TT/A/2012/00061	15-Oct-2010			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	Turkmenistan	201290149	15-Oct-2010	30-Dec-2014	020588	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	C	REG	Granted	United States	14187421	05-Mar-2014	10-Feb-2015	6652018	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	C	REG	Filed	United States	141576604	22-Dec-2014			Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Granted	United States	13489778	15-Oct-2010	22-Apr-2014	6703761	Glaxo Group Limited
TAFINLAR (debaratib)	PR63967	ORG	REG	Filed	Vietnam	1-2012-01348	15-Oct-2010			Glaxo Group Limited

Patent No.	Patent Title	IPC Class.	Applicant	Priority Date	Grant Date	Grant Status	Grant Holder	Legal Status
TAFLNLAR (gabapentin)	PR634319	ORG	REG	Filed	European Patent Convention	11825576.7	02-Sep-2011	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR643119	ORG	REG	Filed	Japan	2013-529184	02-Sep-2011	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR643119	ORG	REG	Filed	United States	13/820824	02-Sep-2011	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Australia	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Brazil	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Canada	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	China P. R.	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	European Patent Convention	13535013.4	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	India	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Japan	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Patent Cooperation Treaty	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Republic of Korea	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Russian Federation	PCT/JUS2013/057432	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	United States	13/4422182	30-Aug-2013	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Australia	20130307043	12-Oct-2010	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Brazil	BR112012008619-0	12-Oct-2010	Glaxo Group Limited
TAFLNLAR (gabapentin)	PR652119	ORG	REG	Filed	Canada	2777561	12-Oct-2010	Glaxo Group Limited

EXECUTION VERSION

Patent No.	Case No.	Type	Filing No.	Case Type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Taiwan	096114746	04-May-2009	01-Apr-2014	1432430	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Tajikistan	201001686	04-May-2009	07-Oct-2013	016846	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Thailand	0901001985	04-May-2009			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Turkmenistan	TT/A/2010/00199	04-May-2009			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Turkmenistan	201001686	04-May-2009	07-Oct-2013	016846	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	United States	13/755486	31-Jan-2013	04-Feb-2014	8642759	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	C	C1	REG	Granted	United States	14/082598	25-Nov-2013			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	C	C2	REG	Filed	United States	12/434353	04-May-2009	09-Aug-2011	7994185	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG	T	REG	Granted	United States	12/931004	04-May-2009	09-Apr-2013	8415345	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Uruguay	31.806	04-May-2009			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Venezuela	2009-000793	04-May-2009			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Vietnam	1-2010-03267	04-May-2009			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Algeria	120180	15-Oct-2010			Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Armenia	20120149	15-Oct-2010	30-Dec-2014	020686	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Australia	2010306553	15-Oct-2010	05-Feb-2014	2010306553	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Azerbaijan	20120149	15-Oct-2010	30-Dec-2014	020686	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Granted	Belarus	20120149	15-Oct-2010	30-Dec-2014	020686	Glaxo Group Limited
TAFINLAR (gabapentin)	PR62987	ORG		REG	Filed	Brazil	BR112012/0088548	15-Oct-2010			Glaxo Group Limited

EXECUTION VERSION

Patent No.	Patent Title	Patent Type	Patent Status	Patent Class	Patent Office	Patent Number	Patent Date	Patent Owner
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	European Patent Convention	10781176.2	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Israel	216363	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Japan	2012-513237	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	Mexico	MX/A/2011/012668	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Republic of Korea	10-2011-7031236	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	Singapore	201108419-1	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	South Africa	201106874	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	United States	13/521577	27-May-2010	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Patent Cooperation Treaty	PCT/US2013/071822	26-Nov-2013	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	United States	11/850688	08-Jan-2007	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	United States	12/141622	18-Jun-2008	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	United States	11/858671	09-Nov-2006	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Algeria	100748	04-May-2009	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Filed	Argentina	P090101596	04-May-2009	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	Armenia	201001660	04-May-2009	Glaxo Group Limited
PROMACTA (telomerase)	PUS6693	ORG	REG	Granted	Australia	2009244491	04-May-2009	Glaxo Group Limited

		Patent No.	Patent Title	Patent Type	Patent Class	Patent Status	Patent Date	Patent Number	Patent Owner		
PROMACTA (EU/000000001)	PUS2444	C	C1	REG	Granted	United States	126607266	28 Oct-2008	06 Dec-2011	8071129	Glaxo Group Limited
PROMACTA (EU/000000002)	PUS2444	C	C2	REG	Granted	United States	126607281	28 Oct-2009	08 Nov-2011	8052993	Glaxo Group Limited
PROMACTA (EU/000000003)	PUS2444	C	C3	REG	Granted	United States	126607305	28 Oct-2009	08 Nov-2011	8052994	Glaxo Group Limited
PROMACTA (EU/000000004)	PUS2444	C	C4	REG	Granted	United States	126607330	28 Oct-2009	22 Nov-2011	8052995	Glaxo Group Limited
PROMACTA (EU/000000005)	PUS2444	C	C5	REG	Granted	United States	126607330	28 Oct-2009	08 Nov-2011	8052995	Glaxo Group Limited
PROMACTA (EU/000000006)	PUS2444	C	C5	REG	Granted	United States	132723667	13 Oct-2011	09 Sep-2014	8828490	Glaxo Group Limited
PROMACTA (EU/000000007)	PUS2444	C	C7	REG	Filed	United States	134505669	04 Aug-2014			Glaxo Group Limited
PROMACTA (EU/000000008)	PUS2444	ORG		REG	Filed	Uruguay	30 512	27 Jul-2007			Glaxo Group Limited
PROMACTA (EU/000000009)	PUS2444	ORG		REG	Filed	Venezuela	1649/2007	01 Aug-2007			Glaxo Group Limited
PROMACTA (EU/000000010)	PUS2444	ORG		REG	Filed	Vietnam	1-2007-01561	31 Jul-2007			Glaxo Group Limited
PROMACTA (EU/000000011)	PUS2444	ORG		REG	Filed	European Patent Convention	09821457.5	14 Oct-2009			Glaxo Group Limited
PROMACTA (EU/000000012)	PUS2444	C	C1	REG	Filed	United States	14180112	08 Jan-2014			Glaxo Group Limited
PROMACTA (EU/000000013)	PUS3545	ORG		REG	Granted	United States	13318550	05 May-2010	02 Jul-2013	8476349	Glaxo Group Limited
PROMACTA (EU/000000014)	PUS3593	ORG		REG	Granted	Australia	2010254046	27 May-2010	27 Feb-2014	2010254045	Glaxo Group Limited
PROMACTA (EU/000000015)	PUS3593	ORG		REG	Filed	Brazil	014014549-5	27 May-2010			Glaxo Group Limited
PROMACTA (EU/000000016)	PUS3593	ORG		REG	Filed	Canada	2763793	27 May-2010			Glaxo Group Limited
PROMACTA (EU/000000017)	PUS3593	D	D1	REG	Filed	China P.R.	201410340006.5	18 Jul-2014			Glaxo Group Limited
PROMACTA (EU/000000018)	PUS3593	ORG		REG	Filed	Eurasian Patent Convention	201171462	27 May-2010			Glaxo Group Limited

EXECUTION VERSION

70

Patent No.	Case No.	Position Type Code	Filing No.	Case Type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Mexico	MX/A-2009/008822	15-Feb-2008	11-Sep-2012	303302	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Moldova	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Republic of Korea	10-2009-7019224	15-Feb-2008	29-Sep-2014	10-144763	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Russian Federation	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Singapore	2009/05327-3	15-Feb-2008	29-Feb-2012	154699	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	South Africa	2009/05332	15-Feb-2008	28-Apr-2010	2009/05332	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Tajikistan	2009/0776	15-Feb-2008	29-Feb-2013	017715	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329	ORG		REG	Granted	Turkmenistan	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329-3	C	C1	REG	Granted	United States	13487512	04-Jun-2012	28-Jan-2014	8637663	Glaxo Group Limited
PROVACTA (elionb0929)	PL62329-3	C	C3	REG	Filed	United States	14231667	30-May-2014			Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Granted	Algeria	07493	01-Aug-2007	30-Mar-2010	5326	Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Filed	Argentina	P070103365	01-Aug-2007			Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	D	D1	REG	Granted	Australia	2012201286	02-Mar-2012	14-Aug-2014	2012201286	Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	D	D2	REG	Filed	Australia	2014202367	30-Apr-2014			Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Granted	Australia	2007352668	01-Aug-2007	22-Mar-2012	2007352609	Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Filed	Bangladesh	1732007	30-Jul-2007			Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Filed	Brazil	PI0721651-3	01-Aug-2007			Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Granted	Canada	265831	01-Aug-2007	28-Nov-2013	265831	Glaxo Group Limited
PROVACTA (elionb0929)	PL62444	ORG		REG	Filed	Chile	2007-2242	01-Aug-2007			Glaxo Group Limited

EXECUTION VERSION

69

Patent No.	Case No.	Type	Filing No.	Case Type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
PROMACTA (ellomibopag)	P51352	ORG		REG	Filed	Venezuela	8052003	19-May-2003			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2325	ORG		REG	Granted	Japan	2005-514195	29-Apr-2004	06-Jan-2012	4836807	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	C	C1	REG	Filed	United States	14/100660	09-Dec-2013			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2325-3	C	C3	REG	Filed	United States	14/253209	02-Jun-2014			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Armenia	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Australia	2008216106	15-Feb-2008	24-Oct-2013	2008216106	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Azerbaijan	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Belarus	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Filed	Brazil	P10807940-4	15-Feb-2008			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Filed	Canada	2678358	15-Feb-2006			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	China P.R.	200860012426.7	15-Feb-2008	12-Mar-2014	ZL200860012426.7	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Eurasian Patent Convention	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Filed	European Patent Convention	06729939.2	15-Feb-2008			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Filed	Indonesia	WO0200802266	15-Feb-2008			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Filed	Israel	200319	15-Feb-2008			Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Japan	2009-550145	15-Feb-2008	04-Apr-2014	5511331	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Kazakhstan	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited
PROMACTA (ellomibopag)	PUG2329	ORG		REG	Granted	Kyrgyzstan	2009/0776	15-Feb-2008	28-Feb-2013	017715	Glaxo Group Limited

LON3401065M 155114-0031

PATENT

REEL: 035806 FRAME: 0515

EXECUTION VERSION

Patent No.	Patent Title	Patent Type	Patent Status	Patent Owner	Patent Number	Patent Date	Patent Term	Patent Class	Patent Subclass
PROMACTA	P51352	ORG	REG	Granted	Slovak Republic	EP1534390	21-May-2003	23-Dec-2009	EP231
PROMACTA	P51352	ORG	REG	Granted	Slovenia	P200331773	21-May-2003	23-Dec-2009	EP1534390
PROMACTA	P51352	ORG	C	Granted	Solomon Islands	J37302	07-Mar-2012	21-Mar-2012	J37302
PROMACTA	P51352	ORG	REG	Granted	South Africa	2004/8701	21-May-2003	22-Feb-2006	2004/8701
PROMACTA	P51352	ORG	REG	Granted	Spain	EP1534390	21-May-2003	23-Dec-2009	2338108
PROMACTA	P51352	ORG	REG	Granted	Sweden	0373-335.0	21-May-2003	23-Dec-2009	EP1534390
PROMACTA	P51352	ORG	REG	Granted	Switzerland	0373-335.0	21-May-2003	23-Dec-2009	EP1534390
PROMACTA	P51352	ORG	PTE	Filed	Taiwan	92113526	31-Dec-2010		1280128
PROMACTA	P51352	ORG	REG	Granted	Taiwan	92113526	20-May-2003	01-May-2007	TR20100199414
PROMACTA	P51352	ORG	REG	Granted	Turkey	EP1534390	21-May-2003	23-Dec-2009	10160
PROMACTA	P51352	ORG	C	Granted	Turks & Caicos	10160	08-Mar-2012	19-Nov-2013	10160
PROMACTA	P51352	ORG	REG	Granted	Tuvalu	EP1534390	09-Mar-2012	28-May-2012	TVP1534390
PROMACTA	P51352	ORG	REG	Granted	United Kingdom	03731335.0	21-May-2003	23-Dec-2009	EP1534390
PROMACTA	P51352	C	REG	Granted	United States	12472819	27-May-2009	14-Sep-2010	7765263
PROMACTA	P51352	C	REG	Granted	United States	12813365	01-Sep-2010	03-Jan-2012	8088813
PROMACTA	P51352	C	REG	Granted	United States	14030973	10-Oct-2013	30-Sep-2014	8846024
PROMACTA	P51352	C	REG	Filed	United States	14478134	05-Sep-2014		
PROMACTA	P51352	ORG	REG	Granted	United States	10515304	21-May-2003	16-Jun-2009	7547719
PROMACTA	P51352	ORG	C	Filed	Vanuatu	X	06-Mar-2012		Glaxo Group Limited

EXECUTION VERSION

64

Patent No.	Case No.	Type	Filing No.	Class	Status	Country	Application Number	Application Date	Granted Date	Patent Number	Legal Owner
PROMACTA	P51141	C	C1	REG	Granted	United States	14567277	11-Dec-2014	13-Jan-2015	8932940	Glaxo Group Limited
PROMACTA	P51141	C	C2	REG	Granted	United States	11620260	05-Jan-2007	19-Feb-2009	7332481	Glaxo Group Limited
PROMACTA	P51141	C	C3	REG	Granted	United States	11620261	08-Jan-2007	06-Jan-2009	7473866	Glaxo Group Limited
PROMACTA	P51141	C	C4	REG	Granted	United States	11620262	08-Jan-2007	18-Nov-2008	7462974	Glaxo Group Limited
PROMACTA	P51141	C	C6	REG	Granted	United States	127141379	18-Jun-2008	09-Mar-2010	7674867	Glaxo Group Limited
PROMACTA	P51141	C	C7	REG	Granted	United States	127141387	18-Jan-2008	07-Sep-2010	7730704	Glaxo Group Limited
PROMACTA	P51141	ORG	PTE	J	Granted	United States	7160970	15-Jan-2008	23-Aug-2012	7180970	Glaxo Group Limited
PROMACTA	P51141	ORG		REG	Granted	United States	10289088	24-May-2001	09-Jan-2007	7160970	Glaxo Group Limited
PROMACTA	P51141	ORG		C	Granted	Vanuatu	22082	05-Aug-2008	05-Aug-2008	22082	Glaxo Group Limited
PROMACTA	P51141	ORG		REG	Filed	Venezuela	2001-001132	25-May-2001			Glaxo Group Limited
PROMACTA	P51352	ORG	PTE	J	Granted	Australia	2003241587	10-Nov-2010	19-Apr-2011	2003241587	Glaxo Group Limited
PROMACTA	P51352	ORG		REG	Granted	Australia	2003241587	21-May-2003	17-Jan-2008	2003241587	Glaxo Group Limited
PROMACTA	P51352	ORG		REG	Granted	Austria	EP1534390	21-May-2003	23-Dec-2008	E452683	Glaxo Group Limited
PROMACTA	P51352	ORG		REG	Granted	Belgium	03731335.0	21-May-2003	23-Dec-2009	EP1534390	Glaxo Group Limited
PROMACTA	P51352	ORG		C	Filed	Bermuda	430EP	17-Feb-2012			Glaxo Group Limited
PROMACTA	P51352	ORG		REG	Filed	Brazil	P10310094.4	21-May-2003			Glaxo Group Limited
PROMACTA	P51352	ORG		C	Granted	British Virgin Islands	EP1534390	13-Feb-2012	22-May-2012	382112012	Glaxo Group Limited
PROMACTA	P51352	ORG		C	Granted	Burundi	RE2012/0012	21-May-2003	03-Apr-2012	RE2012/0012	Glaxo Group Limited
PROMACTA	P51352	ORG	PTE	J	Granted	Bulgaria	10/004	14-May-2010	27-Nov-2012	2010/0004	Glaxo Group Limited

LON30110594 15514-0031

PATENT

REEL: 035806 FRAME: 0517

EXECUTION VERSION

41

Patent No.	Case No.	Patent Type	Filing No.	Case Type	Status	Country	Application Number	Approval Date	Grant Date	Patent Number	Legal Owner
AKT	PUB5185	ORG		REG	Filed	Singapore	11201406409V	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	South Africa	2014/07345	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	Taiwan	102114114	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	Thailand	1401006421	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	Thailand & Tobago	TT/A/2014/00144	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	United States	14/394394	22-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	Uruguay	34762	23-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5185	ORG		REG	Filed	Venezuela	2013/470	24-Apr-2013			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5274	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2013/065827	21-Oct-2013			GlaxoSmithKline LLC
AKT	PUB5275	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2013/065829	21-Oct-2013			GlaxoSmithKline LLC
AKT	PUB5575	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2014/064996	01-Oct-2014			GlaxoSmithKline Intellectual Property (No. 2) Limited
AKT	PUB5576	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2014/064997	01-Oct-2014			GlaxoSmithKline Intellectual Property (No. 2) Limited

LDN3601104594 155114-0031

PATENT

REEL: 035806 FRAME: 0518

EXECUTION VERSION

Patent No.	Case No.	Retention type Code	Filing No.	Case type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
AKT	PUB55671	ORG	P	L	Filed	United States	614051640	12-Mar-2014			GlaxoSmithKline Intellectual Property No. 21 Limited
ARRANON (atumumab)	PE0515	D	D1PTE	J	Granted	Russian Federation	9500446704	13-May-2009	12-Aug-2009	2112765	Glaxo Group Limited
ARRANON (atumumab)	PE0515	C	C10	REG	Granted	United States	98110487	29-Aug-1993	13-Jun-1995	5424295	Glaxo Group Limited
ARRANON (atumumab)	PE0515	ORG	C10PTE	J	Granted	United States	5424295	15-Dec-2005	25-Feb-2010	5424295	Glaxo Group Limited
ARRANON (atumumab)	PE1166	ORG	PTE	J	Granted	Japan	2007-70122	22-Nov-2007	09-Jul-2008	2673086	Glaxo Group Limited
ARRANON (atumumab)	PE1166	ORG	PTE	J	Granted	Russian Federation	9500486004	13-May-2009	12-Aug-2009	2114860	Glaxo Group Limited
ARRANON (atumumab)	PE1166	C	C2	REG	Granted	United States	06443073	24-May-1995	13-Oct-1996	5621236	Glaxo Group Limited
ARRANON (atumumab)	PE1166	C	C3	REG	Granted	United States	06443073	31-May-1995	05-May-1996	5747472	Glaxo Group Limited
ARRANON (atumumab)	PE04478	ORG		REG	Filed	European Patent Convention	127342129	10-Jan-2012			GlaxoSmithKline Intellectual Property Management Limited
ARRANON (atumumab)	PE04478	ORG		REG	Filed	Japan	2013-548515	10-Jan-2012			GlaxoSmithKline Intellectual Property Management Limited
ARRANON (atumumab)	PE04478	ORG		REG	Filed	United States	13/076723	10-Jan-2012			GlaxoSmithKline Intellectual Property Management Limited
ARRANON (atumumab)	PE04478	ORG		REG	Granted	Algeria	100067	03-Jul-2008	04-Sep-2011	6953	GlaxoSmithKline LLC
ARRANON (atumumab)	PE04478	ORG		REG	Filed	Argentina	P080102910	04-Jul-2008			GlaxoSmithKline LLC
ARRANON (atumumab)	PE04478	ORG		REG	Granted	Armenia	201070105	03-Jul-2008	30-Apr-2013	017964	GlaxoSmithKline LLC
ARRANON (atumumab)	PE04478	D	D1	REG	Docketed	Australia	TBA				GlaxoSmithKline LLC
ARRANON (atumumab)	PE04478	ORG		REG	Granted	Australia	2008275276	03-Jul-2008	28-Jul-2011	2008275276	GlaxoSmithKline LLC
ARRANON (atumumab)	PE04478	ORG		REG	Granted	Azerbaijan	201070105	03-Jul-2008	30-Apr-2013	017964	GlaxoSmithKline LLC

EXECUTION VERSION

45

Applicant	Case No.	Relation type	Filing No.	Case type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Philippines	1-2008-EC249	03-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	D	D1	REG	Doctelad	Republic of Korea	TBA	TBA			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Republic of Korea	10-2010-7000148	03-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	D	D1	REG	Doctelad	Russian Federation	TBA	TBA			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Granted	Russian Federation	201070105	03-Jul-2008	30-Apr-2013	017984	GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Granted	Singapore	200908688-5	03-Jul-2008	15-Mar-2013	158240	GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Granted	South Africa	200908707	03-Jul-2008	27-Dec-2012	200909107	GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Taiwan	97125245	04-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Granted	Tajikistan	201070105	03-Jul-2008	30-Apr-2013	017994	GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Thailand	0801003469	04-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Trinidad & Tobago	TT/A/2010/00002	03-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Granted	Turkmenistan	201070105	03-Jul-2008	30-Apr-2013	017994	GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	D	D1	REG	Filed	United States	14/613881	19-Feb-2015			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	United States	12/657860	03-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Uruguay	31210	04-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Venezuela	1326/2006	04-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU62528	ORG		REG	Filed	Vietnam	1-2010-0-00320	03-Jul-2008			GlaxoSmithKline LLC
ARZERRA (atumumab)	PU65585	ORG	P	L	Filed	United States	51/982978	23-Apr-2014			GlaxoSmithKline Intellectual Property

LON34710992 135174-0331

PATENT

REEL: 035806 FRAME: 0520

EXECUTION VERSION

45

Patent No.	Case No.	IPC Class.	Filing No.	IPC Class	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
H/CAMTIN (transfmb)	1-3-6	ORG		C	Granted	Bahrain	64097	30-Apr-1997	05-Jul-1998	BP1162	Glaxo Group Limited
H/CAMTIN (transfmb)	P60004	F	C1	REG	Granted	United States	08471026	27-Mar-1985	07-Oct-1997	5674872	Glaxo Group Limited
H/CAMTIN (transfmb)	PU60518	C	C1	REG	Granted	United States	12770893	30-Apr-2010	17-Apr-2012	8156645	Glaxo Group Limited
H/CAMTIN (transfmb)	PU60518	ORG		REG	Granted	United States	10870880	12-Nov-2004	13-Jul-2010	7754733	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	Australia	2010298277	23-Sep-2010	18-Oct-2014	2010298277	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Brazil	BR112012006693.5	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Canada	2775124	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	China P.R.	201090052971.0	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Eurasian Patent Convention	201270445	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	European Patent Convention	10819435.6	23-Sep-2010	12-Nov-2014	EP2480084	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	France	10819435.8	23-Sep-2010	12-Nov-2014	EP2480084	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	Germany	EP2480084	23-Sep-2010	12-Nov-2014	602010020283.1	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Israel	218797	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	Italy	10819435.8	23-Sep-2010	12-Nov-2014	EP2480084	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Japan	2012-531018	23-Sep-2010			Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Granted	Mexico	MX/A/2012/003646	23-Sep-2010	23-Jun-2014	321448	Glaxo Group Limited
MEKINIST (transfmb)	PU63937	ORG		REG	Filed	Republic of Korea	10-2012-7010303	23-Sep-2010			Glaxo Group Limited

LON34911049/A 15314-0031

PATENT

REEL: 035806 FRAME: 0521

EXECUTION VERSION

47

Patent No.	Creation Date	Creation Type	Filing No.	Class Type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
MEKINIST (tametnb)	PJ63937	ORG		REG	Granted	Singapore	201202013.7	23-Sep-2010	23-Dec-2014	176564	Glaxo Group Limited
MEKINIST (tametnb)	PJ63937	ORG		REG	Granted	South Africa	2012/02173	23-Sep-2010	28-Nov-2012	2012/02173	Glaxo Group Limited
MEKINIST (tametnb)	PJ63937	ORG		REG	Granted	Spain	10819425.8	23-Sep-2010	12-Nov-2014	EP2480084	Glaxo Group Limited
MEKINIST (tametnb)	PJ63937	ORG		REG	Granted	United Kingdom	10819425.8	23-Sep-2010	12-Nov-2014	EP2480084	Glaxo Group Limited
MEKINIST (tametnb)	PJ63937	C	C1	REG	Filed	United States	14/270774	06-May-2014			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	Australia	201209280	23-Sep-2010	16-Dec-2014	201209280	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Brazil	BR112012006486-1	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Canada	2776125	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	China P.R.	201080052873.X	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Eurasian Patent Convention	201270453	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	European Patent Convention	10819428.2	23-Sep-2010	12-Nov-2014	EP2480085	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	France	10819428.2	23-Sep-2010	12-Nov-2014	EP2480085	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	Germany	EP2480085	23-Sep-2010	12-Nov-2014	602010020265.8	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Israel	218901	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	Italy	10819428.2	23-Sep-2010	12-Nov-2014	EP2480086	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Japan	2012-531020	23-Sep-2010			Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Granted	Mexico	MX/A/2012/003547	23-Sep-2010	24-Jun-2014	321356	Glaxo Group Limited
MEKINIST (tametnb)	PJ63938	ORG		REG	Filed	Republic of Korea	10-2012-7010301	23-Sep-2010			Glaxo Group Limited

LON140110494 15/11/14-0031

PATENT

REEL: 035806 FRAME: 0522

Case No.	Applicant	Inventor	IPC Class	Type	Status	Country	Application Number	Filing Date	Grant Date	Patent Number	Legal Owner
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Singapore	2012018164	23-Sep-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Granted		South Africa	2012/01940	23-Sep-2010	28-Nov-2012	2012/01940	Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Granted		Spain	10819438.2	23-Sep-2010	12-Nov-2014	EP2480085	Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Granted		United Kingdom	10619438.2	23-Sep-2010	12-Nov-2014	EP2480085	Glaxo Group Limited
MEKINIST (framehb)	PUB63993	C	REG	Filed		United States	14/317773	27-Jun-2014	12-Nov-2014		Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Granted		Australia	2016322105	17-Nov-2010	21-Aug-2014	2016322105	Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Brazil	BR112012011677-0	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Canada	2781053	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	D	REG	Filed		China P.R.	201410636441.1	11-Oct-2014			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		China P.R.	201090061682.7	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Eurasian Patent Convention	201290339	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		European Patent Convention	10632068.0	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Israel	219786	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Japan	2012-536983	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Mexico	MX/A/2012/006768	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Filed		Republic of Korea	10-2012-7015509	17-Nov-2010			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	D	REG	Filed		Singapore	10201407558T	14-Nov-2014			Glaxo Group Limited
MEKINIST (framehb)	PUB63993	ORG	REG	Granted		South Africa	2012/03444	17-Nov-2010	27-Feb-2013	2012/03444	Glaxo Group Limited

EXECUTION VERSION

49

Patent No.	Case No.	Type	Filing No.	Type	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
MEKINIST (trametinib)	PUB3993	C	C1	REG	Filed	United States	14/309202	19-Jun-2014			Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	European Patent Convention	11764240.1	19-May-2011	07-Jan-2015	EP2571359	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	France	11764240.1	19-May-2011	07-Jan-2015	EP2571358	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	Germany	11764240.1	19-May-2011	07-Jan-2015	EP2571356	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	Italy	11764240.1	19-May-2011	07-Jan-2015	EP2571358	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Filed	Japan	2013-511357	19-May-2011			Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	Spain	11764240.1	19-May-2011	07-Jan-2015	EP2571358	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Granted	United Kingdom	11764240.1	19-May-2011	07-Jan-2015	EP2571358	Glaxo Group Limited
MEKINIST (trametinib)	PUB4244	ORG		REG	Filed	United States	13/889077	19-May-2011			Glaxo Group Limited
MEKINIST (trametinib)	PUB4326	ORG		REG	Filed	European Patent Convention	11820572.3	24-Aug-2011			GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trametinib)	PUB4326	ORG		REG	Filed	Japan	2013-526118	24-Aug-2011			GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trametinib)	PUB4326	C	C1	REG	Filed	United States	14/327860	10-Jul-2014			GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trametinib)	PUB4408	ORG		REG	Filed	European Patent Convention	11838853.5	04-Nov-2011			GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trametinib)	PUB4408	ORG		REG	Filed	Japan	2013-537854	04-Nov-2011			GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trametinib)	PUB4408	ORG		REG	Filed	United States	13/883374	04-Nov-2011			GlaxoSmithKline Intellectual Property (No. 2) Limited

LON340114694 135134-0031

PATENT

REEL: 035806 FRAME: 0524

	Patent No.	Filing Date	Applicant Name	Application Number	Priority Date	Grant Date	Patent Number	Legal Owner		
MEKINIST (trade/nhb)	PUB4460	ORG	REG	Filed	European Patent Convention	11951046.0	20-Dec-2011	GlaxoSmithKline Intellectual Property (No. 2) Limited		
MEKINIST (trade/nhb)	PUB4460	ORG	REG	Filed	Japan	2013-546309	20-Dec-2011	GlaxoSmithKline Intellectual Property (No. 2) Limited		
MEKINIST (trade/nhb)	PUB4460	ORG	REG	Granted	United States	13891676	20-Dec-2011	09-Dec-2014	8909879	GlaxoSmithKline Intellectual Property (No. 2) Limited
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Algeria	130458	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Argentina	20110104773	19-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Australia	2011349422	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	\$	Filed	Bangladesh	29112011	18-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Brazil	BR112013015602-3	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Canada	2822701	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Chile	2013-1779	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	China P.R.	201130066861.0	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Colombia	13-150559	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	
MEKINIST (trade/nhb)	PUB4461	ORG	REG	Filed	Costa Rica	PCT/JUS2011096021	20-Dec-2011		GlaxoSmithKline Intellectual Property (No. 2) Limited	

REEL: 035806 FRAME: 0526

MEKINIST (trade/nhb)	PUB4461	C	TC1	REG	Filed	United States	14/04/139	02-Oct-2013				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	C	TC2	REG	Filed	United States	14/10/092	11-Dec-2013				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	C	TC3	REG	Filed	United States	14/10/193	11-Dec-2013				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	ORG	T	REG	Granted	United States	13/30/843	20-Dec-2011	12-Nov-2013	8560364		GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	ORG		REG	Filed	Uruguay	33-818	19-Dec-2011				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	ORG		REG	Filed	Venezuela	1696/2011	20-Dec-2011				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB4461	ORG		REG	Filed	Vietnam	1-2013-02260	20-Dec-2011				GlaxoSmithKline Intellectual Property (No 2) Limited
MEKINIST (trade/nhb)	PUB5281	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2013/06954	24-Oct-2013				Glaxo Group Limited
MEKINIST (trade/nhb)	PUB5345	ORG		REG	Filed	Argentina	20130104892	28-Nov-2013				Glaxo Group Limited
MEKINIST (trade/nhb)	PUB5345	ORG		REG	Filed	Bangladesh	264/2013	28-Nov-2013				Glaxo Group Limited
MEKINIST (trade/nhb)	PUB5345	ORG		REG	Filed	Gulf Cooperation Council	25882	28-Nov-2013				Glaxo Group Limited
MEKINIST (trade/nhb)	PUB5345	ORG		REG	Filed	Jordan	344/2013	28-Nov-2013				Glaxo Group Limited
MEKINIST (trade/nhb)	PUB5345	ORG		REG	Filed	New Zealand	628395	25-Nov-2013				Glaxo Group Limited

EXECUTION VERSION

54

Patent No.	Patent Title	Patent Type	Patent Status	Patent Country	Application Number	Application Date	Grant Date	Patent Number	Local Owner
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Pakistan	84/2013	28-Nov-2013		Gleco Group Limited
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Pakistan Cooperation Treaty	PCT/US2013/071816	28-Nov-2013		Gleco Group Limited
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Taiwan	10244386	28-Nov-2013		Gleco Group Limited
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Uruguay	35157	28-Nov-2013		Gleco Group Limited
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Venezuela	14812013	27-Nov-2013		Gleco Group Limited
MEKINIST (patent)	PUB5346	ORG	REG	Filed	Argentina	20140102081	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5400	ORG	REG	Filed	Bangladesh	1487014	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Gulf Cooperation Council	201427234	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Jordan	1712014	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	New Zealand	628535	27-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Pakistan	4002014	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Patent Cooperation Treaty	PCT/JP2014/031757	27-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Taiwan	103115201	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited
MEKINIST (patent)	PUB5480	ORG	REG	Filed	Uruguay	35537	26-May-2014		GlecoSmithKline Intellectual Property (No.2) Limited

Patent No.	Inventor	Filing Date	Type	Status	Country	Applicant	Date of Grant	Grant Date	Patent Number	Legal Owner	
MEKINIST (transnb)	PUS6480	ORG		REG	Filed	Venezuela	2014/655	27-May-2014		GlaxoSmithKline Intellectual Property (No 2) Limited	
MEKINIST (transnb)	PUS6487	ORG		REG	Filed	Patent Cooperation Treaty	PCT/AUS2014/039698	28-May-2014		Glaxo Group Limited & Menck Sharp & Dornme Ltd	
MEKINIST (transnb)	PUS6488	ORG		REG	Filed	Patent Cooperation Treaty	PCT/IB2014/061895	02-Jun-2014		GlaxoSmithKline Intellectual Property (No 2) Limited	
MEKINIST (transnb)	PUS6545	ORG		REG	Filed	Patent Cooperation Treaty	PCT/IB2014/065899	24-Oct-2014		GlaxoSmithKline Intellectual Property (No 2) Limited	
MEKINIST (transnb)	PUS6610	ORG		REG	Filed	Patent Cooperation Treaty	PCT/IB2014/066814	11-Dec-2014		GlaxoSmithKline Intellectual Property (No 2) Limited	
MEKINIST (transnb)	PUS6632	ORG		REG	Filed	Patent Cooperation Treaty	PCT/US2015/010403	07-Jan-2015		Glaxo Group Limited	
MEKINIST (transnb)	PUS6633	ORG		REG	Filed	Patent Cooperation Treaty	PCT/AUS2014/035991	30-Apr-2014		Glaxo Group Limited	
PROMACIA (transnb)	PUS6735	ORG		REG	Granted	Australia	1999012951	30-Oct-1998	03-Jan-2002	738473	Glaxo Group Limited
PROMACIA (transnb)	PUS6735	X	1	REG	Granted	United States	08/6300307	29-Nov-2000	28-Aug-2001	6280958	Glaxo Group Limited
PROMACIA (transnb)	PUS1141	D	D1	REG	Filed	Argentina	P080101957	02-May-2008			Glaxo Group Limited
PROMACIA (transnb)	PUS1141	ORG		REG	Filed	Argentina	P010102468	23-May-2001			Glaxo Group Limited
PROMACIA (transnb)	PUS1141	ORG	PTE	J	Granted	Australia	2001274838	10-Nov-2010	28-Apr-2011	2001274838	Glaxo Group Limited
PROMACIA (transnb)	PUS1141	ORG		REG	Granted	Australia	2001274938	24-May-2001	04-May-2006	2001274838	Glaxo Group Limited
PROMACIA (transnb)	PUS1141	D	D1	REG	Granted	Austria	EP1894981	17-Aug-2007	22-Jul-2009	E437162	Glaxo Group Limited
PROMACIA (transnb)	PUS1141	D	D2	REG	Granted	Austria	EP1888838	17-Aug-2007	14-Oct-2009	E445806	Glaxo Group Limited

8

EXECUTION VERSION

Patent No.	Case No.	Type	Form	Class	State	Country	Applying Number	App Date	Grant Date	Grant Number	Legal Owner
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Slovenia	95941825.2	20-Nov-1995	06-Sep-2000	0792149	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	South Africa	95.9820	20-Nov-1995	25-Sep-1996	95.9820	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Spain	95941825.2	20-Nov-1995	06-Sep-2000	0792149	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Sweden	95941825.2	20-Nov-1995	06-Sep-2000	0792149	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Switzerland	95941825.2	20-Nov-1995	06-Sep-2000	0792148	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Taiwan	84113264	13-Dec-1995	01-Dec-2000	NI123925	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		C	Granted	Turkish Cyprus	XX	20-Nov-1995	03-Aug-2000	71	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	United Kingdom	9523866.7	20-Nov-1995	25-Nov-1996	2295317	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	United States	08.347331	20-Nov-1995	29-Dec-1998	6854270	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		REG	Granted	Zanzibar	XX	20-Nov-1995	08-Jun-2000	4.2000	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2047	ORG		C	Granted	Zanzibar	XX	20-Nov-1995	08-Jun-2000	4.2000	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		C	Granted	Antigua	03/2000	29-Jun-2000	03-Jan-2003	03/2000	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		REG	Granted	Austria	0783495	20-Nov-1995	31-May-2000	E193444	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		C	Granted	Bahrain	1032.2000	07-May-2000	07-Feb-2001	BP1351	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		REG	Granted	Belgium	09500955	21-Nov-1995	07-Apr-1998	1010250A3	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		REG	Granted	Brazil	PI9509806.9	20-Nov-1995	23-May-2006	PI9509806.9	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		REG	Granted	Canada	2205600	20-Nov-1995	30-May-2000	2205600	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		C	Granted	Chile	1999.3155	28-Dec-1999	10-Nov-2005	42.508	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		REG	Granted	China P.R.	95181726.X	20-Nov-1995	08-Mar-2002	ZL95181726.X	GlaxoSmithKline Inc.
ZOF-RAN (ondansetron)	GC2076	ORG		C	Granted	Cyprus	CY00.00011	20-Nov-1995	10-Sep-2002	CY2166	GlaxoSmithKline Inc.

EXECUTION VERSION

87

Patent No.	Case No.	Relation Type Code	Filing No.	Case Type Code	Status	Country	Application Number	Application Date	Grant Date	Patent Number	Legal Owner
ZOF-RAN (undesignated)	GC2076	ORG		REG	Granted	Taiwan	84112791	30-Nov-1995	21-Jul-2000	NL118090	GlaxoSmithKline Inc.
ZOF-RAN (undesignated)	GC2075	ORG		C	Granted	Turkish Cyprus	XX	20-Nov-1996	03-Aug-2000	72	GlaxoSmithKline Inc.
ZOF-RAN (undesignated)	GC2076	ORG		REG	Granted	United Kingdom	9523687.5	20-Nov-1995	26-Oct-1998	2293318	GlaxoSmithKline Inc.
ZOF-RAN (undesignated)	GC2076	C	C3	REG	Granted	United States	08 099762	28-Apr-1998	21-Sep-1999	5653488	GlaxoSmithKline Inc.
ZOF-RAN (undesignated)	GC2075	C	C4	REG	Granted	United States	08 238165	28-Jan-1999	16-May-2000	6063802	GlaxoSmithKline Inc.
ZOF-RAN (undesignated)	GC2075	ORG		C	Granted	Zanzibar	XX	20-Nov-1995	08-Jun-2000	PG-2000	GlaxoSmithKline Inc.

SCHEDULE 1, PART 2

Assigned Abandoned Patent Applications

LON34011040/4 155114-0031

PATENT

RECORDED: 06/02/2015

REEL: 035806 FRAME: 0531